中国药理学通报
中國藥理學通報
중국약이학통보
CHINESE PHARMACOLOGICAL BULLETIN
2015年
1期
71-76
,共6页
郎艳松%秘红英%刘红利%袁国强
郎豔鬆%祕紅英%劉紅利%袁國彊
랑염송%비홍영%류홍리%원국강
动脉粥样硬化%滋养血管%血管内皮生长因子%彩色微球%通心络超微粉%阿司匹林%阿托伐他汀
動脈粥樣硬化%滋養血管%血管內皮生長因子%綵色微毬%通心絡超微粉%阿司匹林%阿託伐他汀
동맥죽양경화%자양혈관%혈관내피생장인자%채색미구%통심락초미분%아사필림%아탁벌타정
atherosclerosis%vasa vasorum%VEGF%color microsphere%Tongxinluo supermicropowder%Atorvasta-tin%Aspirin
目的:观察通心络联合阿托伐他汀、阿司匹林对家兔动脉粥样硬化早期颈动脉外膜滋养血管新生的影响。方法72只健康♀♂各半新西兰白兔随机分为对照组、模型组、通心络(TXL)组、阿托伐他汀(ATO)组、阿司匹林(ASP)组、金三角(ATS)[1]组,各12只。对照组给予普通饲料、模型组及各用药组家兔均实施单侧颈动脉硅胶管包裹术复合高脂饲料喂养,TXL 组给予通心络超微粉混悬液0.3 g·kg-1· d-1灌胃,ATO 组给予阿托伐他汀2.5 mg·kg-1·d-1灌胃, ASP 组给予阿司匹林12 mg·kg-1·d-1灌胃,ATS 组给予通心络超微粉混悬液0.3 g·kg-1·d-1加阿托伐他汀2.5 mg ·kg-1·d-1加阿司匹林12 mg·kg-1·d-1灌胃,连续给药4周后取材,HE 染色观察颈动脉内中膜的变化;免疫组化法检测颈动脉外膜CD34表达情况;微球检测颈动脉微血管血流量的变化;RT-PCR 和Western blot 检测颈动脉组织中 VEGF、VEGFR-2基因和蛋白表达情况。结果与对照组比较,模型组VEGF、VEGFR-2基因和蛋白表达以及微血管血流量明显增强(P <0.01)。与模型组比较,各用药组VEGF、 VEGFR-2基因和蛋白表达以及微血管血流量明显减弱(P <0.01,P <0.05)。与其他用药组比较,ATS 组VEGF、VEGFR- 2基因和蛋白表达以及微血管血流量明显减弱(P <0.01,P <0.05)。与ASP 组比较,TXL 组、ATO 组VEGFR-2蛋白表达均明显降低(P <0.05),ATO 组微血管血流量减少明显(P <0.05)。TXL 组与ATO 组两组间比较差异无显著性(P >0.05)。VEGF、VEGFR-2基因和VEGF 蛋白表达组间比较无统计学意义(P >0.05)。各用药组颈动脉外膜CD34表达减少。结论“ATS”方案有助于减少动脉粥样硬化早期颈动脉VEGF、VEGFR-2表达,抑制血管外膜滋养血管新生,减少促炎物质进入血管中膜、内膜,延缓动脉粥样硬化进程。
目的:觀察通心絡聯閤阿託伐他汀、阿司匹林對傢兔動脈粥樣硬化早期頸動脈外膜滋養血管新生的影響。方法72隻健康♀♂各半新西蘭白兔隨機分為對照組、模型組、通心絡(TXL)組、阿託伐他汀(ATO)組、阿司匹林(ASP)組、金三角(ATS)[1]組,各12隻。對照組給予普通飼料、模型組及各用藥組傢兔均實施單側頸動脈硅膠管包裹術複閤高脂飼料餵養,TXL 組給予通心絡超微粉混懸液0.3 g·kg-1· d-1灌胃,ATO 組給予阿託伐他汀2.5 mg·kg-1·d-1灌胃, ASP 組給予阿司匹林12 mg·kg-1·d-1灌胃,ATS 組給予通心絡超微粉混懸液0.3 g·kg-1·d-1加阿託伐他汀2.5 mg ·kg-1·d-1加阿司匹林12 mg·kg-1·d-1灌胃,連續給藥4週後取材,HE 染色觀察頸動脈內中膜的變化;免疫組化法檢測頸動脈外膜CD34錶達情況;微毬檢測頸動脈微血管血流量的變化;RT-PCR 和Western blot 檢測頸動脈組織中 VEGF、VEGFR-2基因和蛋白錶達情況。結果與對照組比較,模型組VEGF、VEGFR-2基因和蛋白錶達以及微血管血流量明顯增彊(P <0.01)。與模型組比較,各用藥組VEGF、 VEGFR-2基因和蛋白錶達以及微血管血流量明顯減弱(P <0.01,P <0.05)。與其他用藥組比較,ATS 組VEGF、VEGFR- 2基因和蛋白錶達以及微血管血流量明顯減弱(P <0.01,P <0.05)。與ASP 組比較,TXL 組、ATO 組VEGFR-2蛋白錶達均明顯降低(P <0.05),ATO 組微血管血流量減少明顯(P <0.05)。TXL 組與ATO 組兩組間比較差異無顯著性(P >0.05)。VEGF、VEGFR-2基因和VEGF 蛋白錶達組間比較無統計學意義(P >0.05)。各用藥組頸動脈外膜CD34錶達減少。結論“ATS”方案有助于減少動脈粥樣硬化早期頸動脈VEGF、VEGFR-2錶達,抑製血管外膜滋養血管新生,減少促炎物質進入血管中膜、內膜,延緩動脈粥樣硬化進程。
목적:관찰통심락연합아탁벌타정、아사필림대가토동맥죽양경화조기경동맥외막자양혈관신생적영향。방법72지건강♀♂각반신서란백토수궤분위대조조、모형조、통심락(TXL)조、아탁벌타정(ATO)조、아사필림(ASP)조、금삼각(ATS)[1]조,각12지。대조조급여보통사료、모형조급각용약조가토균실시단측경동맥규효관포과술복합고지사료위양,TXL 조급여통심락초미분혼현액0.3 g·kg-1· d-1관위,ATO 조급여아탁벌타정2.5 mg·kg-1·d-1관위, ASP 조급여아사필림12 mg·kg-1·d-1관위,ATS 조급여통심락초미분혼현액0.3 g·kg-1·d-1가아탁벌타정2.5 mg ·kg-1·d-1가아사필림12 mg·kg-1·d-1관위,련속급약4주후취재,HE 염색관찰경동맥내중막적변화;면역조화법검측경동맥외막CD34표체정황;미구검측경동맥미혈관혈류량적변화;RT-PCR 화Western blot 검측경동맥조직중 VEGF、VEGFR-2기인화단백표체정황。결과여대조조비교,모형조VEGF、VEGFR-2기인화단백표체이급미혈관혈류량명현증강(P <0.01)。여모형조비교,각용약조VEGF、 VEGFR-2기인화단백표체이급미혈관혈류량명현감약(P <0.01,P <0.05)。여기타용약조비교,ATS 조VEGF、VEGFR- 2기인화단백표체이급미혈관혈류량명현감약(P <0.01,P <0.05)。여ASP 조비교,TXL 조、ATO 조VEGFR-2단백표체균명현강저(P <0.05),ATO 조미혈관혈류량감소명현(P <0.05)。TXL 조여ATO 조량조간비교차이무현저성(P >0.05)。VEGF、VEGFR-2기인화VEGF 단백표체조간비교무통계학의의(P >0.05)。각용약조경동맥외막CD34표체감소。결론“ATS”방안유조우감소동맥죽양경화조기경동맥VEGF、VEGFR-2표체,억제혈관외막자양혈관신생,감소촉염물질진입혈관중막、내막,연완동맥죽양경화진정。
Aim To observe the effect of a treatment proposal named “Golden Triangle” ( Atorvastatin, Tongxinluo,and Aspirin) on the vasa vasorum angio-genesis of early atherosclerosis lesions in rabbits carotid artery. Method Seventy-two healthy New Zealand rabbits with half males and half females were divided into 6 groups randomly ( n =12 ):control group, model group, Tongxinluo group ( TXL ) , atorvastatin group ( ATO ) , aspirin group ( ASP ) , golden triangle group ( ATS) . The control group was fed with common feed-stuff, and all the other groups′ right carotid arteries were equipped with the silicone tube,and were then fed with fatty feedstuff. The Tongxinluo group, the Atorvas-tatin group and the Aspirin group were given suspen-sion of Tongxinluo supermicro powder(0. 3 g·kg-1 · d-1 ) , Atorvastatin ( 2. 5 mg · kg-1 · d-1 ) and Aspirin (12 mg·kg-1·d-1),the golden triangle group were given suspension of Tongxinluo supermicropowder (0. 3g·kg-1 ·d-1),atorvastatin(2. 5 mg·kg-1 · d-1 ) and Aspirin ( 12 mg · kg-1 · d-1 ) . All the groups were fed with medicine for 4 weeks. Tissue slice of carotid artery was stained with HE and observed un-der light microscope. The change of blood liquid was detected by biochemical assay. Immunohistochemical staining was used to detect the protein expression of CD34 around the carotid artery adventitia. Color micro-sphere method was used to detect the blood flow vol-ume change of the cartoid artery microvascular. VEFG, VEGFR-2 gene and protein expression in the cartoid artery were detected by Real-time PCR and Western Blot. Result Compared with the control group,the content of VEGF, VEGFR-2 gene and pro-tein expression and the microvascular blood flow vol-ume of cartoid artery microvascular in the model were significantly increased ( P <0. 01 ) . But those in each drug group were lighter than those in the model group (P<0. 01,P <0. 05). In the ATS group,the content of VEGF, VEGFR-2 gene and protein expression and the microvascular blood flow volume of cartoid artery microvascular were lower than those in the TXL, ATO and ASP group ( P <0. 01 , P <0. 05 ) . Compared with the ASP group,the content of VEGFR-2 protein expres-sion was significantly decreased(P<0. 01)in the TXL and ATO group. VEGF,VEGFR-2 gene and protein ex-pression in different subgroups showed no significant difference( P >0. 05 ) . The content of CD34 was de-creased in TongxinLuo group,atorvastatin group,aspirin group and ATS group. Conclusion The ATS project can reduce the expression of VEGF,VEGFR-2, inhibit the vasa vasorum angiogenesis and decrease proinflam-matory substances in the tunica media and intima of vascular wall. It plays an important role in intervening in the process of AS.